Factor XIII Activity
Also known as: F13 A
Use
This test is the preferred first-line diagnostic tool for assessing inherited or acquired factor XIII (FXIII) deficiency. It's especially applicable for patients presenting with a bleeding disorder who have normal prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count. It's also used to monitor FXIII therapy and to confirm any abnormalities detected on FXIII qualitative assays.
Special Instructions
The test is a Laboratory Developed Test (LDT) and is approved in New York state. Samples must be collected and handled following specific guidelines to ensure validity.
Limitations
This test has been developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration, but it is intended for clinical purposes and performed in a CLIA certified laboratory. Inappropriate specimen handling could lead to false results, necessitating adherence to collection instructions.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 27815-0
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
1 mL
Container
ARUP standard transport tube
Collection Instructions
Transfer the platelet-poor plasma to an ARUP standard transport tube after collecting in a lt. blue (sodium citrate) tube. Critical to freeze immediately.
Storage Instructions
Store and transport the specimen in a frozen state.
Causes for Rejection
Serum, EDTA plasma, clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 hours |
| Refrigerated | Unacceptable |
| Frozen | 3 months |